262
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Analytical characterization of recombinant hCG and comparative studies with reference product

, , , , , & show all
Pages 23-35 | Published online: 30 Jan 2018

References

  • FournierTGuibourdencheJEvain-BrionDPlacenta201536Suppl 1S60S6525707740
  • EzcurraDHumaidanPA review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technologyReprod Biol Endocrinol2014129525280580
  • AllahbadiaGRecombinant or urinary human chorionic gonadotropin in ovulation induction?J Obstet Gynaecol India201161662162323204676
  • FonjallazPLoumayeERecombinant hCG (OVIDREL) and recombinant interferon-(beta)1a (REBIF). (No. 13 in a series of articles to promote a better understanding of the use of genetic engineering)J Biotechnol200187327928111411454
  • EleryanMGAkhiyatSRengifo-PardoMEhrlichABiosimilars: potential implications for cliniciansClin Cosmet Investig Dermatol20169135142
  • McCamishMWoollettGThe state of the art in the development of biosimilarsClin Pharmacol Ther201291340541722318617
  • BerkowitzSAEngenJRMazzeoJRJonesGBAnalytical tools for characterizing biopharmaceuticals and the implications for biosimilarsNat Rev Drug Discov201211752754022743980
  • KadamVBagdeSKarpeMKadamVA comprehensive overview on biosimilarsCurr Protein Pept Sci201617875676126916165
  • SimoensSBiosimilar medicines and cost-effectivenessClinicoecon Outcomes Res20113293621935330
  • SchiestlMStanglerTTorellaCCepeljnikTTollHGrauRAcceptable changes in quality attributes of glycosylated biopharmaceuticalsNat Biotechnol201129431031221478841
  • ICHICH Harmonised Tripartite GuidelineComparability of Biotechnological/Biological Product Subject to Changes in their Manufacturing Process Q5E2005
  • TsurutaLRLopes dos SantosMMoroAMBiosimilars advancements: moving on to the futureBiotechnol Prog20153151139114925708573
  • ICHICH Harmonised Tripartite GuidelinePharmaceutical Development Q8 (R2)2009
  • ICHICH Harmonised Tripartite GuidelineDevelopment and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities) Q112012
  • VisserJFeuersteinIStanglerTSchmiedererTFritschCSchiestlMPhysicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximabBioDrugs201327549550723649935